An Index of Cannabis-Related Terms and Definitions Used in Atalis

Across all of the cannabis data, intelligence and insight accessible through Atalis, there are a number of cannabis-related terms and definitions we use to describe certain categories and subcategories. 

Below, we’ve compiled an initial list of these terms: a list which will continue to grow organically in unison with the Atalis platform and be updated regularly. The date of last update is included at the bottom of this page. 

CBD/Hemp Industry

Refers to CBD products that do not strictly fit the definition of medicinal CBD in the sense that they are not intended for treating specific conditions and are available outside of medical routes, e.g. they don’t require a doctor prescription or recommendation.

They are generally obtained from industrial hemp, which contains very low amounts of THC (under 0.3% depending on country legislation).

CBD Wellness

CBD wellness products refer to a wide range of products from food and beverages to nutrition supplements to oils and dermal patches as well as vaporising and inhalation devices. Rather than being produced and advertised for treating medical conditions, wellness CBD is marketed more for the relaxing and physical and mental well-being that CBD products can provide consumers, as well as mild self-medicating potential.

Refers to CBD products sold as finished goods (branded and B2C) not intended for treating specific conditions and are available without prescription, mostly as FMCG (fast-moving consumer goods) or OTC products.

We include capsules, oils/tinctures and other innovative products such as dermal patches, puffers and suppositories in this category, as well as sports balms and creams (for joint pain, muscle recovery and inflammation).

CBD-containing e-liquids for vaping, CBD-infused foods and beverages and CBD cosmetics are considered separate categories (different from CBD wellness) otherwise stated differently in the scope of the project. 

CBD Wholesale Products

CBD wholesale products are considered either:CBD-containing hemp extracts sold in bulk including full and broad-spectrum oil and resin, distillates, isolates, crude oil, sold in bulk as wholesale product (B2B)

CBD-containing whitelabel products sold in bulk through B2B channels, aimed at brands without vertically integrated supply chain. 

CBD topicals: CBD products for topical application where CBD is the main ingredient. 

CBD cosmetics: Cosmetic products for topical application where CBD is not the main ingredient.

Pharmaceutical Cannabis

Formulated, processed, or synthetic cannabis sold as finished products, which has undergone full medical trials and holds (in one or more geographical areas) a medical marketing authorisation* e.g. Cesamet®, Marinol®, Syndros®, Sativex®, Epidiolex® and any derived generic medicines or;

Cannabinoid-based API (Active Pharmaceutical Ingredient), which is registered as an API in a medicinal product holding marketing authorisation* in one or more geographies, to be manipulated and/or compounded by a magistral pharmacy to produce a cannabinoid-based medicine

*Granted by the FDA, EMA or other EMA-affiliated agencies (or any agencies holding Mutual Recognition Agreement with these agencies).

Medical Cannabis

Cannabinoid-based medicine not holding marketing authorisation and therefore sold as an unlicensed medicine supplied through health systems and prescribed by a doctor or;

Active Pharmaceutical Ingredient (API) to be manipulated and/or compounded by a magistral pharmacy in order to prepare a cannabinoid-based medicine without marketing authorisation (unlicensed).

For countries that have classified cannabis as a non-medical product to be used in healthcare (such as Brazil), we consider all cannabis products as medical cannabis unless they have undergone extensive clinical trials with successful application for a medical marketing authorization in another country.

Pharmaceutical Cannabis Industry

Formulated, processed, or synthetic cannabis sold as finished products, which has undergone full medical trials and holds (in one or more geographical areas) a medical marketing authorisation* e.g. Cesamet®, Marinol®, Syndros®, Sativex®, Epidiolex® and any derived generic medicines. 

Or, cannabinoid-based API (Active Pharmaceutical Ingredient), which is registered as an API in a medicinal product holding marketing authorisation* in one or more geographies, to be manipulated and/or compounded by a magistral pharmacy to produce a cannabinoid-based medicine

*Granted by the FDA, EMA or other EMA-affiliated agencies (or any agencies holding Mutual Recognition Agreement with these agencies).

Medical Cannabis

Cannabinoid-based medicine not holding marketing authorisation and therefore sold as an unlicensed medicine supplied through health systems and prescribed by a doctor or;

Active Pharmaceutical Ingredient (API) to be manipulated and/or compounded by a magistral pharmacy in order to prepare a cannabinoid-based medicine without marketing authorisation (unlicensed).

For countries that have classified cannabis as a non-medical product to be used in healthcare (such as Brazil), we consider all cannabis products as medical cannabis unless they have undergone extensive clinical trials with successful application for a medical marketing authorization in another country.

Cannabinoids

Cannabinoids are chemical compounds primarily found in cannabis and produced by the human body which interact with our endocannabinoid system. The main ones are THC and CBD, while also including minor ones such as CBG and CBN. 

Cannabidiol (CBD)

One of the main cannabinoids which can be extracted from the cannabis sativa plants (mostly low THC hemp). CBD exhibits wide-ranging properties useful for health and wellness including anti-anxiety, anti-inflammatory, anti-pain, anti-arthritic and neuroprotective effects. CBD is indicated for treatment of conditions such as epilepsy and is commonly used for conditions such as pain and insomnia.

Tetrahydrocannabinol (THC)

Main psychoactive cannabinoid produced by cannabis plants, mostly in their flowering tops.

Note: it is very important to notice the difference between CBD as a cannabinoid and CBD as a type of cannabis or industry. CBD as a compound is present in cannabis products of all types: including medicinal and recreational cannabis. However the CBD industry is focused in the non-controlled uses of this cannabinoid, generally sourced from industrial hemp. 

Last updated on Monday 15 March 2021. 

Latest News

Adult-Use Cannabis Legalisation in Europe: The Final Countdown Begins

16 Jul 2021

In this insightful article, international cannabis expert, Barbara Pastori, explores the potential impact of adult-use legalisation in Europe.

Uruguay on the Cusp of Legalising CBD Edibles

09 Jul 2021

The Uruguayan government is considering proposed changes to regulations which could see edible non-psychoactive cannabis products legalised.

PREVIEW: The Cannabis Extraction Report – Webinar

01 Jul 2021

Prohibition Partners were joined by Always Pure Organics & Vitalis Extraction Technology for a preview of the report.